BioNano Genomics Inc vs Global X Cloud Computing ETF — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Global X Cloud Computing ETF trades at $24.16. The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CLOU | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.92 | $26.38 |
52-Week Low | $1.09 | $17.60 |
Enterprise Value | $15.81M | — |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
CLOU trades at $24.11, up 1.49% with a bullish technical signal from moving averages. The ETF shows strong institutional interest in cloud computing exposure but faces mixed oscillators with RSI indicating overbought conditions. Recent news highlights both opportunity in underperforming tech sectors and concerns about cloud ETF performance trends.
The outlook balances cloud computing's growth potential against valuation concerns and sector volatility. Investment opportunity lies in AI-driven cloud adoption, while risks include competitive pressures and the ETF's historical underperformance compared to broader tech indices.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →